Exposure to TNF inhibitors is rare at MOGAD presentation

Zara P.;Cauli A.;Solla P.;Sechi E.
2022-01-01
2022
Adverse event; Demyelination; MOGAD; Myelin oligodendrocyte glycoprotein; Tumor necrosis factor
Files in This Item:
File Size Format  
PDF CAULI 1-s2.0-S0022510X21027465-main.pdf

Solo gestori archivio

Type: versione editoriale
Size 484.79 kB
Format Adobe PDF
& nbsp; View / Open   Request a copy
484.79 kB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie